Skip to main content

Teams led by Dr. Bryan Roth, MD, PhD and Dr. Grégory Scherrer, PharmD, PhD, have developed a groundbreaking molecular technology to reduce pain by targeting peripheral nervous system (PNS) nociceptors.

Bryan Roth and Gregory Scherrer Teams figure from Cell Paper published Dec. 26, 2024.
Structure of mHCAD chemogenetic system in complex with FCH-2296413 (magenta), an inert drug-like compound. Credit: Kang et. al (2024).
Using a chemogenetic tool designed by the Roth lab and insights from research from the Scherrer group on pain neurobiology, these groups successfully reduced acute and tissue-injury-induced inflammatory pain in mouse models. This innovative approach could potentially lead to new treatments for chronic pain.
Their paper describing this innovative approach, “Structure-guided design of a peripherally restricted chemogenetic system,” was published online in Cell Dec. 3.

 

Citation:
Kang HJ, Krumm BE, Tassou A, Geron M, DiBerto JF, Kapolka NJ, Gumpper RH, Sakamoto K, Dewran Kocak D, Olsen RHJ, Huang XP, Zhang S, Huang KL, Zaidi SA, Nguyen MT, Jo MJ, Katritch V, Fay JF, Scherrer G, Roth BL. Structure-guided design of a peripherally restricted chemogenetic system. Cell. 2024 Dec 26;187(26):7433-7449.e20. Epub 2024 Dec 3.

 

The paper has been highlighted here: